id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-297010-imciixde	Babayeva, Mariana	Repurposing Drugs for COVID-19: Pharmacokinetics and Pharmacogenomics of Chloroquine and Hydroxychloroquine	2020-10-23		.txt	text/plain	7080	519	48	81 Similar doses of the two drugs produced 11-fold variations in the blood concentrations in patients with rheumatoid arthritis 47, 63, 82, 83 and in healthy volunteers, 52, 64 suggesting different extend of metabolism among individuals. Determination of CYP3A, CYP2C8 and CYP2D6 polymorphism and, therefore, activity is important to establish safe and efficient dosing of chloroquine and hydroxychloroquine for treatment of COVID-19 patients. 125 Overall, the results suggest that CYP2C8, CYP2D6 and CYP3A genetic polymorphisms may influence chloroquine and hydroxychloroquine pharmacokinetics and COVID-19 patients treated with the same dose of CQ or HCQ may exhibit lack of efficacy or adverse reactions. Despite the evidence of the influence of genetic polymorphisms on the pharmacokinetics of chloroquine and hydroxychloroquine, no large pharmacogenomics studies have been conducted to provide guidance on the use, dosing, and duration of the therapy in COVID-19 patients.	./cache/cord-297010-imciixde.txt	./txt/cord-297010-imciixde.txt